Sai Gutti, MD
Interventional Pain Medicine · Pikeville, KYNPI 1992805410
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,566 of the $9,014 with a category attached, or 72.8%. 50 manufacturers reported payments, led by AbbVie at 35.9% of the total.
Across 363 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pacira Pharmaceuticals Incorporated$1K
- Biogen$997
- Teva Pharmaceuticals USA, Inc.$326
- Merck$314
- Novartis$307
- plus $3K from 44 others
What the payments were for
- Speaking & faculty fees$1,64118%
- Travel & lodging$8069%
- Food & beverage$6,56673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,014 in reported general payments places this provider in the 80th percentile of 55 interventional pain medicine providers in Kentucky.
See all interventional pain medicine providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 39 | $13,890 |
| Fentanyl | 76 | $7,864 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 140 | $3,834 |
| Oxycodone Hcl | 168 | $2,772 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 221 | $2,595 |
| Celecoxib | 190 | $2,408 |
| Duloxetine Hcl | 232 | $2,391 |
| Dronabinol | 17 | $1,890 |
| Morphine Sulfate ErMorphine Sulfate | 78 | $1,565 |
| Naloxone Hcl | 27 | $1,294 |
| Gabapentin | 86 | $582 |
| Tizanidine Hcl | 76 | $291 |
| Methocarbamol | 32 | $240 |
| Tramadol Hcl | 27 | $167 |
| Oxcarbazepine | 11 | $153 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Pikeville
- Robert KlickovichFlorence$57K
- Hammad MalikRichmond$35K
- Michael FletcherFlorence$18K
- Vishal BansalMadisonville$13K
- Anand ModaduguLexington$12K
- Zachary KlingerCorbin$10K
- Nathan LambornLouisville$10K
- Brock MarrsLexington$9K
- Brandon SuttonLouisville$9K
- Gary ReasorLouisville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.